MITO
Price:
$0.32
Market Cap:
$0
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to tr...[Read more]
Industry
Biotechnology
IPO Date
2019-02-15
Stock Exchange
NASDAQ
Ticker
MITO
According to Stealth BioTherapeutics Corp’s latest financial reports and current stock price. The company's current ROE is 193.18%. This represents a change of 394.33% compared to the average of 39.08% of the last 4 quarters.
The mean historical ROE of Stealth BioTherapeutics Corp over the last ten years is 56.64%. The current 193.18% ROE has changed 241.07% with respect to the historical average. Over the past ten years (40 quarters), MITO's ROE was at its highest in in the December 2020 quarter at 176.80%. The ROE was at its lowest in in the March 2020 quarter at -640.30%.
Average
56.64%
Median
28.78%
Minimum
-415.41%
Maximum
553.96%
Discovering the peaks and valleys of Stealth BioTherapeutics Corp ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 553.96%
Minimum Annual Increase = -1761.01%
Minimum Annual ROE = -415.41%
Year | ROE | Change |
---|---|---|
2021 | 118.71% | -78.57% |
2020 | 553.96% | -233.35% |
2019 | -415.41% | -1761.01% |
2018 | 25.01% | -12.14% |
2017 | 28.46% | -2.17% |
The current ROE of Stealth BioTherapeutics Corp (MITO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
85.76%
5-year avg
62.15%
10-year avg
56.64%
Stealth BioTherapeutics Corp’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Stealth BioTherapeutics Corp using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Stealth BioTherapeutics Corp or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Stealth BioTherapeutics Corp's ROE?
How is the ROE calculated for Stealth BioTherapeutics Corp (MITO)?
What is the highest ROE for Stealth BioTherapeutics Corp (MITO)?
What is the 3-year average ROE for Stealth BioTherapeutics Corp (MITO)?
What is the 5-year average ROE for Stealth BioTherapeutics Corp (MITO)?
How does the current ROE for Stealth BioTherapeutics Corp (MITO) compare to its historical average?